Gilead Sciences (GILD) stock in focus as its twice-yearly HIV PrEP therapy lenacapavir, is approved in the EU as Yeytuo for HIV prevention. Read more here.

Kite Pharma will buy Interius BioTherapeutics for $350 million in cash to add an in vivo CAR‑T platform that creates T‑cell ...

Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

Getting your Trinity Audio player ready… On July 23rd, Gilead Sciences presented The Time Is Now: Let’s End HIV In Our Communities press briefing in Chicago, Illinois.

Kite, a Gilead Company, has announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 ...

These were among the concerns of a recent regulatory inspection of a key, but historically troubled, manufacturing plant that ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...